Traffic Roots Audience Pixel
Protectx

A safer future isn’t just something we wish for.

We’re creating it.

OUR MISSION:
TO DELIVER NEXT-GEN ARRAYS FOR BETTER HEALTH AND SAFETY.
State-Of-Art Performance
DNA and RNA-based pathogen testing kits from PathogenDx are light years ahead of other microbial testing methods. In addition to being able to test for dozens of different microbials simultaneously, testing kits from PathogenDx provide:
Ultra-Rapid
The PathogenDx Microarray platform enables high-specificity detection of a broad range microbial threats, in a single test, in less than 6 hours from new sample to result.
Scalable. Unbeatable.
Forget the one and done. The PathogenDx Microarray iinterrogates dozens of threats in a single test—with rapid adaptability—helping labs drive unprecedented throughput.
Automated Prep
Our latest innovation, Octa AutoPrep Station, delivers “set it and forget it” ease for sample prep, reducing hands-on steps, time to results and the potential for human error.
Lowest Cost
Given the dramatic efficiencies of our platform, and the addition of new automated sample prep, PathogenDx is driving down the cost of every single test and every lab process.
Maximum Detection
If it’s there, we’ll identify it, with detection and quantification down to 1CFU/gram for pathogenic organisms.
Consumables Down, ROI Up
Unlike other technologies, we’ve simplified sample prep. One sample prep for all assays, reducing the cost and environmental waste of consumables.
WE ARE A TEAM OF PASSIONATE MOLECULAR SCIENTISTS COLLABORATING TO DESIGN TESTING SYSTEMS BASED ON OUR WORLD-CLASS MICROARRAY TECHNOLOGY.
WE DELIVER MOLECULAR ASSAYS THAT INTERROGATE MULTIPLE TARGETS IN THE SAME REACTION ACROSS SAMPLE TYPES
OUR ASSAYS DELIVER SINGLE GENE COPY SENSITIVITY, AND SINGLE NUCLEOTIDE RESOLUTIONS.
How the multiplex works
Zooming graphic of the technology inside the PathogenDx Microarray.
A sample goes through hybridization inside a PathogenDX Microarray.
The sample is scanned, illuminating the florescent dye.
Safer Every Day: Updates
  • PathogenDx Is Headed To AAFP: Introducing SeroX

     

    This year, PathogenDx is proud to sponsor the Arkansas Association of Food Protection (AAFP) Conference, and introduce the Future of Safe in Poultry with its SeroX assay. Developed on our highly multiplexed and patented D3 Array™, PathogenDx now delivers ultra-rapid Salmonella detection and Serotyping in a single well reaction, at a fraction of the cost, time and effort of conventional methods.

    INTRODUCING SEROX
    This new Assay delivers advanced gene detection of Salmonella and all currently proposed and future USDA FSIS serotypes. SeroX ensures the simplified workflow, agility and cost savings the poultry industry needs to optimize their production lots and ensure safety and quality. Benefits include:

    • Industry-leading test turnaround time
    • Best-in-Class cost per sample
    • Minimize hold times and storage costs
    • Ensure freshness of product and shelf life
    • Future-proof testing—detect today’s Serotypes and add tomorrow’s

    Stop by and see us at AAFP! In the meantime, you can learn more at pathogendx.com/food.

    More »
  • Introducing D3 Array™-UTI to the Executive War College

    Today, a wide range of urinary tract conditions are considered either complex or recurrent, creating the need for more complete and rapid insight.

    Introducing PathogenDx D3 Array™-UTI to Executive War College. This is a fast multiplexed testing solution for urinary pathogen detection run simultaneously with antibiotic resistance gene markers. This novel highly multiplexed UTI assay provides a scalable, low cost solution in a single test with results in under 6.5 hours.

    Test for 26 causative pathogens + 12 Antibiotic Resistance Genes in a single test, with qualitative detection and quantification in the same sample reaction. This multiplexed assay delivers unrivaled insight in a single test, with same-shift results.

    Learn more at https://pathogendx.com/uti/

    More »
The future of safe
Learn more about PathogenDx and the Future of Safe: